(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces changes in the leadership team of its Polish subsidiary “Helix Polska”. The appointments are effective as of January, 28, 2016.
- 0 Comments
- FY2016